Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)
Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy, ...
Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday?
We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...
pharmaphorum13h
Sarepta slumps on Elevidys patient death
The tragic death of the 16-year-old boy came as a result of acute liver failure, which is a known side effect of Elevidys and ...
Sarepta’s Gene Therapy Under Scrutiny After Patient Death
The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, The Associated Press reported. However, the "severity" of this case had not ...
BioSpace13h
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...
Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Sarepta weakness ‘compelling’ buying opportunity, says Mizuho
Mizuho views the selloff in shares of Sarepta (SRPT) yesterday due to concerns about Elevidys adoption as a result of the fatal acute liver ...
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
MPR7h
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.